A clinical study of CL2020 in patients with epidermolysis bullosa

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080224498

Enrollment

Registered

2018-12-20

Start date

2018-12-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis bullosa

Interventions

investigational material(s) Generic name etc : CL2020 INN of investigational material : - Therapeutic category code : 49- Other agents affecting cellular function Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Major inclusion criteria Patients with epidermolysis bullosa who have any intractable ulcers Patients aged 12 to 75 years Female or male patients

Exclusion criteria

Exclusion criteria: Major exclusion criteria Patients with any existing or previous malignant tumor Female patients who are or may be pregnant or who are breastfeeding

Design outcomes

Primary

Measure	Time frame
safety Safety after infusion of CL2020	—

Secondary

Measure	Time frame
efficacy efficacy after infusion of CL2020	—

Countries

Japan

Contacts

Public Contactcall center

Life Science Institute Inc.

lsii.chiken-inq@eppharmaline.co.jp+81-3-6748-7200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026